7th August 2026, Friday

TechPharus

Latest Posts

HealthTech News

  • Gene mutations behind serious bone marrow conditions identified
    on August 7, 2026 at 12:00 am

    Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow’s ability to produce sufficient healthy blood cells. Patients with these disorders are also at increased risk of developing myelodysplastic syndromes—MDS—a group of blood cancers in which the bone marrow produces excess abnormal blood cells and insufficient healthy ones.

  • Wildfire smoke sends more Oregonians to emergency rooms
    on August 6, 2026 at 11:00 pm

    Days of poor air quality from thick wildfire smoke are pushing more Oregonians into emergency rooms and urgent care clinics, state health officials say.

  • Immune-inspired public health strategy improves detection of disease-carrying insects
    on August 6, 2026 at 10:40 pm

    A disease surveillance strategy modeled on the body’s immune system detected more disease-carrying insects than the traditional top-down approach, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania and the Universidad Peruana Cayetano Heredia in Peru.

  • Trauma analysis finds brain injuries more common among e-scooter riders than motorcyclists
    on August 6, 2026 at 10:20 pm

    E-scooter riders in England and Wales may face a higher risk of brain and internal organ injuries than motorcyclists and cyclists, according to a study published in Scientific Reports. The authors recommend increasing e-scooter safety through measures including mandatory helmet legislation, stricter speed limits and e-scooter design improvements such as deformable handlebar grips and enhanced braking.

  • FDA approves first drug for full range of narcolepsy symptoms
    on August 6, 2026 at 10:00 pm

    The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved drug to directly target the loss of orexin signaling that causes the disease.